Mycophenolate mofetil: Effects on clinical transplantation

Curtis D. Holt, Theodore M. Sievers, Rafik M. Ghobrial, Steven J. Rossi, John A. Goss, Sue V. McDiarmid

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalBioDrugs
Volume10
Issue number5
DOIs
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Mycophenolate mofetil: Effects on clinical transplantation'. Together they form a unique fingerprint.

Cite this